Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Axogen reports 23% Q2 revenue growth, raises 2026 guidance

Jul 29, 2026, 7:11 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive growth metrics, reaffirmed guidance, and meaningful pipeline validations reduce downside risk and improve the likelihood of multiple expansion. Non-GAAP profitability and cash generation reinforce upside potential, especially if REPOSE and NERVE-RESTORE milestones translate into broader access and adoption.

AI summary

What happened, with direct paths to the underlying reporting

Axogen posted a solid Q2 with $69.7 million in revenue, up 23.1% y/y and a 72.7% gross margin, pressured by product mix, notably breast. The company reaffirmed 2026 targets: at least 24% revenue growth to $279 million and positive free cash flow. Pipeline validation via REPOSE and Nerve-RESTORE and a minority stake in Trace Biosciences reinforce growth catalysts and potential beyond-device adoption.

Revenue $69.7M; up 23.1% year over year.
Gross margin 72.7% vs 74.2%; Breast mix impacts mix.
Net loss $1.5M; Adjusted net income $7.3M; Adjusted EBITDA $8.4M.
2026 guidance: revenue growth at least 24% to $279M; positive free cash flow.
REPOSE and Nerve-RESTORE add Level 1 evidence; Trace Biosciences stake.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Axogen reports 23% Q2 revenue growth, raises 2026 guidance

FDA approves Axogen's nerve repair graft

AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates